Global Adeno-Associated Virus (AAV) Vector Production CDMO Market Outlook, In‑Depth Analysis & Forecast to 2031

1 Study Coverage
1.1 Introduction to Adeno-Associated Virus (AAV) Vector Production CDMO: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Adeno-Associated Virus (AAV) Vector Production CDMO Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Adherent Culture
1.2.3 Suspension Culture
1.3 Market Segmentation by Application
1.3.1 Global Adeno-Associated Virus (AAV) Vector Production CDMO Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Vaccine Development
1.3.3 Gene Therapy
1.3.4 Academic Scientific Research Institution
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Adeno-Associated Virus (AAV) Vector Production CDMO Revenue Estimates and Forecasts 2020-2031
2.2 Global Adeno-Associated Virus (AAV) Vector Production CDMO Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020-2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends
3 Competition by Players
3.1 Global Adeno-Associated Virus (AAV) Vector Production CDMO Player Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2020-2025)
3.1.2 Global Key Player Revenue Ranking (2023 vs. 2024)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Player (2020 VS 2024)
3.2 Global Adeno-Associated Virus (AAV) Vector Production CDMO Companies Headquarters and Service Footprint
3.3 Main Product Type Market Size by Players
3.3.1 Adherent Culture Market Size by Players
3.3.2 Suspension Culture Market Size by Players
3.4 Global Adeno-Associated Virus (AAV) Vector Production CDMO Market Concentration and Dynamics
3.4.1 Global Market Concentration (CR5 and HHI)
3.4.2 Entrant/Exit Impact Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Adeno-Associated Virus (AAV) Vector Production CDMO Revenue Trends by Type
4.1.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.1.2 Global Revenue Market Share by Type (2020-2031)
4.2 Key Product Attributes and Differentiation
4.3 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.3.1 High-Growth Niches and Adoption Drivers
4.3.2 Profitability Hotspots and Cost Drivers
4.3.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Adeno-Associated Virus (AAV) Vector Production CDMO Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.1.2 Revenue Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application
6 North America
6.1 North America Market Size (2020-2031)
6.2 North America Key Players Revenue in 2024
6.3 North America Adeno-Associated Virus (AAV) Vector Production CDMO Market Size by Type (2020-2031)
6.4 North America Adeno-Associated Virus (AAV) Vector Production CDMO Market Size by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Adeno-Associated Virus (AAV) Vector Production CDMO Market Size by Country
6.6.1 North America Revenue Trends by Country
6.6.2 US
6.6.3 Canada
6.6.4 Mexico
7 Europe
7.1 Europe Market Size (2020-2031)
7.2 Europe Key Players Revenue in 2024
7.3 Europe Adeno-Associated Virus (AAV) Vector Production CDMO Market Size by Type (2020-2031)
7.4 Europe Adeno-Associated Virus (AAV) Vector Production CDMO Market Size by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Adeno-Associated Virus (AAV) Vector Production CDMO Market Size by Country
7.6.1 Europe Revenue Trends by Country
7.6.2 Germany
7.6.3 France
7.6.4 U.K.
7.6.5 Italy
7.6.6 Russia
8 Asia-Pacific
8.1 Asia-Pacific Market Size (2020-2031)
8.2 Asia-Pacific Key Players Revenue in 2024
8.3 Asia-Pacific Adeno-Associated Virus (AAV) Vector Production CDMO Market Size by Type (2020-2031)
8.4 Asia-Pacific Adeno-Associated Virus (AAV) Vector Production CDMO Market Size by Application (2020-2031)
8.5 Asia-Pacific Growth Accelerators and Market Barriers
8.6 Asia-Pacific Adeno-Associated Virus (AAV) Vector Production CDMO Market Size by Region
8.6.1 Asia-Pacific Revenue Trends by Region
8.7 China
8.8 Japan
8.9 South Korea
8.10 Australia
8.11 India
8.12 Southeast Asia
8.12.1 Indonesia
8.12.2 Vietnam
8.12.3 Malaysia
8.12.4 Philippines
8.12.5 Singapore
9 Central and South America
9.1 Central and South America Market Size (2020-2031)
9.2 Central and South America Key Players Revenue in 2024
9.3 Central and South America Adeno-Associated Virus (AAV) Vector Production CDMO Market Size by Type (2020-2031)
9.4 Central and South America Adeno-Associated Virus (AAV) Vector Production CDMO Market Size by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Adeno-Associated Virus (AAV) Vector Production CDMO Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Market Size (2020-2031)
10.2 Middle East and Africa Key Players Revenue in 2024
10.3 Middle East and Africa Adeno-Associated Virus (AAV) Vector Production CDMO Market Size by Type (2020-2031)
10.4 Middle East and Africa Adeno-Associated Virus (AAV) Vector Production CDMO Market Size by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Adeno-Associated Virus (AAV) Vector Production CDMO Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Israel
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Thermo Fisher Scientific
11.1.1 Thermo Fisher Scientific Corporation Information
11.1.2 Thermo Fisher Scientific Business Overview
11.1.3 Thermo Fisher Scientific Adeno-Associated Virus (AAV) Vector Production CDMO Product Features and Attributes
11.1.4 Thermo Fisher Scientific Adeno-Associated Virus (AAV) Vector Production CDMO Revenue and Gross Margin (2020-2025)
11.1.5 Thermo Fisher Scientific Adeno-Associated Virus (AAV) Vector Production CDMO Revenue by Product in 2024
11.1.6 Thermo Fisher Scientific Adeno-Associated Virus (AAV) Vector Production CDMO Revenue by Application in 2024
11.1.7 Thermo Fisher Scientific Adeno-Associated Virus (AAV) Vector Production CDMO Revenue by Geographic Area in 2024
11.1.8 Thermo Fisher Scientific Adeno-Associated Virus (AAV) Vector Production CDMO SWOT Analysis
11.1.9 Thermo Fisher Scientific Recent Developments
11.2 Lonza
11.2.1 Lonza Corporation Information
11.2.2 Lonza Business Overview
11.2.3 Lonza Adeno-Associated Virus (AAV) Vector Production CDMO Product Features and Attributes
11.2.4 Lonza Adeno-Associated Virus (AAV) Vector Production CDMO Revenue and Gross Margin (2020-2025)
11.2.5 Lonza Adeno-Associated Virus (AAV) Vector Production CDMO Revenue by Product in 2024
11.2.6 Lonza Adeno-Associated Virus (AAV) Vector Production CDMO Revenue by Application in 2024
11.2.7 Lonza Adeno-Associated Virus (AAV) Vector Production CDMO Revenue by Geographic Area in 2024
11.2.8 Lonza Adeno-Associated Virus (AAV) Vector Production CDMO SWOT Analysis
11.2.9 Lonza Recent Developments
11.3 Catalent
11.3.1 Catalent Corporation Information
11.3.2 Catalent Business Overview
11.3.3 Catalent Adeno-Associated Virus (AAV) Vector Production CDMO Product Features and Attributes
11.3.4 Catalent Adeno-Associated Virus (AAV) Vector Production CDMO Revenue and Gross Margin (2020-2025)
11.3.5 Catalent Adeno-Associated Virus (AAV) Vector Production CDMO Revenue by Product in 2024
11.3.6 Catalent Adeno-Associated Virus (AAV) Vector Production CDMO Revenue by Application in 2024
11.3.7 Catalent Adeno-Associated Virus (AAV) Vector Production CDMO Revenue by Geographic Area in 2024
11.3.8 Catalent Adeno-Associated Virus (AAV) Vector Production CDMO SWOT Analysis
11.3.9 Catalent Recent Developments
11.4 Charles River
11.4.1 Charles River Corporation Information
11.4.2 Charles River Business Overview
11.4.3 Charles River Adeno-Associated Virus (AAV) Vector Production CDMO Product Features and Attributes
11.4.4 Charles River Adeno-Associated Virus (AAV) Vector Production CDMO Revenue and Gross Margin (2020-2025)
11.4.5 Charles River Adeno-Associated Virus (AAV) Vector Production CDMO Revenue by Product in 2024
11.4.6 Charles River Adeno-Associated Virus (AAV) Vector Production CDMO Revenue by Application in 2024
11.4.7 Charles River Adeno-Associated Virus (AAV) Vector Production CDMO Revenue by Geographic Area in 2024
11.4.8 Charles River Adeno-Associated Virus (AAV) Vector Production CDMO SWOT Analysis
11.4.9 Charles River Recent Developments
11.5 Merck
11.5.1 Merck Corporation Information
11.5.2 Merck Business Overview
11.5.3 Merck Adeno-Associated Virus (AAV) Vector Production CDMO Product Features and Attributes
11.5.4 Merck Adeno-Associated Virus (AAV) Vector Production CDMO Revenue and Gross Margin (2020-2025)
11.5.5 Merck Adeno-Associated Virus (AAV) Vector Production CDMO Revenue by Product in 2024
11.5.6 Merck Adeno-Associated Virus (AAV) Vector Production CDMO Revenue by Application in 2024
11.5.7 Merck Adeno-Associated Virus (AAV) Vector Production CDMO Revenue by Geographic Area in 2024
11.5.8 Merck Adeno-Associated Virus (AAV) Vector Production CDMO SWOT Analysis
11.5.9 Merck Recent Developments
11.6 SK pharmteco
11.6.1 SK pharmteco Corporation Information
11.6.2 SK pharmteco Business Overview
11.6.3 SK pharmteco Adeno-Associated Virus (AAV) Vector Production CDMO Product Features and Attributes
11.6.4 SK pharmteco Adeno-Associated Virus (AAV) Vector Production CDMO Revenue and Gross Margin (2020-2025)
11.6.5 SK pharmteco Recent Developments
11.7 Oxford Biomedica
11.7.1 Oxford Biomedica Corporation Information
11.7.2 Oxford Biomedica Business Overview
11.7.3 Oxford Biomedica Adeno-Associated Virus (AAV) Vector Production CDMO Product Features and Attributes
11.7.4 Oxford Biomedica Adeno-Associated Virus (AAV) Vector Production CDMO Revenue and Gross Margin (2020-2025)
11.7.5 Oxford Biomedica Recent Developments
11.8 AGC Biologics（MolMed）
11.8.1 AGC Biologics（MolMed） Corporation Information
11.8.2 AGC Biologics（MolMed） Business Overview
11.8.3 AGC Biologics（MolMed） Adeno-Associated Virus (AAV) Vector Production CDMO Product Features and Attributes
11.8.4 AGC Biologics（MolMed） Adeno-Associated Virus (AAV) Vector Production CDMO Revenue and Gross Margin (2020-2025)
11.8.5 AGC Biologics（MolMed） Recent Developments
11.9 Gene Universal
11.9.1 Gene Universal Corporation Information
11.9.2 Gene Universal Business Overview
11.9.3 Gene Universal Adeno-Associated Virus (AAV) Vector Production CDMO Product Features and Attributes
11.9.4 Gene Universal Adeno-Associated Virus (AAV) Vector Production CDMO Revenue and Gross Margin (2020-2025)
11.9.5 Gene Universal Recent Developments
11.10 Polyplus (Sartorius)
11.10.1 Polyplus (Sartorius) Corporation Information
11.10.2 Polyplus (Sartorius) Business Overview
11.10.3 Polyplus (Sartorius) Adeno-Associated Virus (AAV) Vector Production CDMO Product Features and Attributes
11.10.4 Polyplus (Sartorius) Adeno-Associated Virus (AAV) Vector Production CDMO Revenue and Gross Margin (2020-2025)
11.10.5 Company Ten Recent Developments
11.11 CCRM
11.11.1 CCRM Corporation Information
11.11.2 CCRM Business Overview
11.11.3 CCRM Adeno-Associated Virus (AAV) Vector Production CDMO Product Features and Attributes
11.11.4 CCRM Adeno-Associated Virus (AAV) Vector Production CDMO Revenue and Gross Margin (2020-2025)
11.11.5 CCRM Recent Developments
11.12 FUJIFILM Diosynth Biotechnologies
11.12.1 FUJIFILM Diosynth Biotechnologies Corporation Information
11.12.2 FUJIFILM Diosynth Biotechnologies Business Overview
11.12.3 FUJIFILM Diosynth Biotechnologies Adeno-Associated Virus (AAV) Vector Production CDMO Product Features and Attributes
11.12.4 FUJIFILM Diosynth Biotechnologies Adeno-Associated Virus (AAV) Vector Production CDMO Revenue and Gross Margin (2020-2025)
11.12.5 FUJIFILM Diosynth Biotechnologies Recent Developments
11.13 Biovian
11.13.1 Biovian Corporation Information
11.13.2 Biovian Business Overview
11.13.3 Biovian Adeno-Associated Virus (AAV) Vector Production CDMO Product Features and Attributes
11.13.4 Biovian Adeno-Associated Virus (AAV) Vector Production CDMO Revenue and Gross Margin (2020-2025)
11.13.5 Biovian Recent Developments
11.14 Miltenyi Bioindustry
11.14.1 Miltenyi Bioindustry Corporation Information
11.14.2 Miltenyi Bioindustry Business Overview
11.14.3 Miltenyi Bioindustry Adeno-Associated Virus (AAV) Vector Production CDMO Product Features and Attributes
11.14.4 Miltenyi Bioindustry Adeno-Associated Virus (AAV) Vector Production CDMO Revenue and Gross Margin (2020-2025)
11.14.5 Miltenyi Bioindustry Recent Developments
11.15 Aldevron
11.15.1 Aldevron Corporation Information
11.15.2 Aldevron Business Overview
11.15.3 Aldevron Adeno-Associated Virus (AAV) Vector Production CDMO Product Features and Attributes
11.15.4 Aldevron Adeno-Associated Virus (AAV) Vector Production CDMO Revenue and Gross Margin (2020-2025)
11.15.5 Aldevron Recent Developments
11.16 Takara Bio
11.16.1 Takara Bio Corporation Information
11.16.2 Takara Bio Business Overview
11.16.3 Takara Bio Adeno-Associated Virus (AAV) Vector Production CDMO Product Features and Attributes
11.16.4 Takara Bio Adeno-Associated Virus (AAV) Vector Production CDMO Revenue and Gross Margin (2020-2025)
11.16.5 Takara Bio Recent Developments
11.17 Yposkesi
11.17.1 Yposkesi Corporation Information
11.17.2 Yposkesi Business Overview
11.17.3 Yposkesi Adeno-Associated Virus (AAV) Vector Production CDMO Product Features and Attributes
11.17.4 Yposkesi Adeno-Associated Virus (AAV) Vector Production CDMO Revenue and Gross Margin (2020-2025)
11.17.5 Yposkesi Recent Developments
11.18 Genezen
11.18.1 Genezen Corporation Information
11.18.2 Genezen Business Overview
11.18.3 Genezen Adeno-Associated Virus (AAV) Vector Production CDMO Product Features and Attributes
11.18.4 Genezen Adeno-Associated Virus (AAV) Vector Production CDMO Revenue and Gross Margin (2020-2025)
11.18.5 Genezen Recent Developments
11.19 Exthera
11.19.1 Exthera Corporation Information
11.19.2 Exthera Business Overview
11.19.3 Exthera Adeno-Associated Virus (AAV) Vector Production CDMO Product Features and Attributes
11.19.4 Exthera Adeno-Associated Virus (AAV) Vector Production CDMO Revenue and Gross Margin (2020-2025)
11.19.5 Exthera Recent Developments
11.20 GenScript ProBio
11.20.1 GenScript ProBio Corporation Information
11.20.2 GenScript ProBio Business Overview
11.20.3 GenScript ProBio Adeno-Associated Virus (AAV) Vector Production CDMO Product Features and Attributes
11.20.4 GenScript ProBio Adeno-Associated Virus (AAV) Vector Production CDMO Revenue and Gross Margin (2020-2025)
11.20.5 GenScript ProBio Recent Developments
11.21 EurekaBio
11.21.1 EurekaBio Corporation Information
11.21.2 EurekaBio Business Overview
11.21.3 EurekaBio Adeno-Associated Virus (AAV) Vector Production CDMO Product Features and Attributes
11.21.4 EurekaBio Adeno-Associated Virus (AAV) Vector Production CDMO Revenue and Gross Margin (2020-2025)
11.21.5 EurekaBio Recent Developments
11.22 Obio Technology
11.22.1 Obio Technology Corporation Information
11.22.2 Obio Technology Business Overview
11.22.3 Obio Technology Adeno-Associated Virus (AAV) Vector Production CDMO Product Features and Attributes
11.22.4 Obio Technology Adeno-Associated Virus (AAV) Vector Production CDMO Revenue and Gross Margin (2020-2025)
11.22.5 Obio Technology Recent Developments
11.23 GeneSail Biotech
11.23.1 GeneSail Biotech Corporation Information
11.23.2 GeneSail Biotech Business Overview
11.23.3 GeneSail Biotech Adeno-Associated Virus (AAV) Vector Production CDMO Product Features and Attributes
11.23.4 GeneSail Biotech Adeno-Associated Virus (AAV) Vector Production CDMO Revenue and Gross Margin (2020-2025)
11.23.5 GeneSail Biotech Recent Developments
11.24 VectorBuilder
11.24.1 VectorBuilder Corporation Information
11.24.2 VectorBuilder Business Overview
11.24.3 VectorBuilder Adeno-Associated Virus (AAV) Vector Production CDMO Product Features and Attributes
11.24.4 VectorBuilder Adeno-Associated Virus (AAV) Vector Production CDMO Revenue and Gross Margin (2020-2025)
11.24.5 VectorBuilder Recent Developments
11.25 WuXi ATU
11.25.1 WuXi ATU Corporation Information
11.25.2 WuXi ATU Business Overview
11.25.3 WuXi ATU Adeno-Associated Virus (AAV) Vector Production CDMO Product Features and Attributes
11.25.4 WuXi ATU Adeno-Associated Virus (AAV) Vector Production CDMO Revenue and Gross Margin (2020-2025)
11.25.5 WuXi ATU Recent Developments
11.26 Ubrigene
11.26.1 Ubrigene Corporation Information
11.26.2 Ubrigene Business Overview
11.26.3 Ubrigene Adeno-Associated Virus (AAV) Vector Production CDMO Product Features and Attributes
11.26.4 Ubrigene Adeno-Associated Virus (AAV) Vector Production CDMO Revenue and Gross Margin (2020-2025)
11.26.5 Ubrigene Recent Developments
11.27 Porton Biologics
11.27.1 Porton Biologics Corporation Information
11.27.2 Porton Biologics Business Overview
11.27.3 Porton Biologics Adeno-Associated Virus (AAV) Vector Production CDMO Product Features and Attributes
11.27.4 Porton Biologics Adeno-Associated Virus (AAV) Vector Production CDMO Revenue and Gross Margin (2020-2025)
11.27.5 Porton Biologics Recent Developments
11.28 Pharmaron
11.28.1 Pharmaron Corporation Information
11.28.2 Pharmaron Business Overview
11.28.3 Pharmaron Adeno-Associated Virus (AAV) Vector Production CDMO Product Features and Attributes
11.28.4 Pharmaron Adeno-Associated Virus (AAV) Vector Production CDMO Revenue and Gross Margin (2020-2025)
11.28.5 Pharmaron Recent Developments
11.29 PackGene Biotechnology
11.29.1 PackGene Biotechnology Corporation Information
11.29.2 PackGene Biotechnology Business Overview
11.29.3 PackGene Biotechnology Adeno-Associated Virus (AAV) Vector Production CDMO Product Features and Attributes
11.29.4 PackGene Biotechnology Adeno-Associated Virus (AAV) Vector Production CDMO Revenue and Gross Margin (2020-2025)
11.29.5 PackGene Biotechnology Recent Developments
12 Adeno-Associated Virus (AAV) Vector Production CDMOIndustry Chain Analysis
12.1 Adeno-Associated Virus (AAV) Vector Production CDMO Industry Chain
12.2 Upstream Analysis
12.2.1 Upstream Key Suppliers
12.3 Middlestream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Adeno-Associated Virus (AAV) Vector Production CDMO Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Adeno-Associated Virus (AAV) Vector Production CDMO Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details

List of Tables
Table 1. Global Adeno-Associated Virus (AAV) Vector Production CDMO Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Adeno-Associated Virus (AAV) Vector Production CDMO Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Adeno-Associated Virus (AAV) Vector Production CDMO Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Adeno-Associated Virus (AAV) Vector Production CDMO Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Adeno-Associated Virus (AAV) Vector Production CDMO Revenue by Region (2026-2031) & (US$ Million)
Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 7. Global Adeno-Associated Virus (AAV) Vector Production CDMO Revenue by Players (2020-2025) & (US$ Million)
Table 8. Global Adeno-Associated Virus (AAV) Vector Production CDMO Revenue Market Share by Players (2020-2025)
Table 9. Global Key Players’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 10. Global Adeno-Associated Virus (AAV) Vector Production CDMO by Player Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Adeno-Associated Virus (AAV) Vector Production CDMO as of 2024)
Table 11. Global Adeno-Associated Virus (AAV) Vector Production CDMO Average Gross Margin (%) by Player (2020 VS 2024)
Table 12. Global Adeno-Associated Virus (AAV) Vector Production CDMO Companies Headquarters
Table 13. Global Adeno-Associated Virus (AAV) Vector Production CDMO Market Concentration Ratio (CR5 and HHI)
Table 14. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 16. Global Adeno-Associated Virus (AAV) Vector Production CDMO Revenue by Type (2020-2025) & (US$ Million)
Table 17. Global Adeno-Associated Virus (AAV) Vector Production CDMO Revenue by Type (2026-2031) & (US$ Million)
Table 18. Key Product Attributes and Differentiation
Table 19. Global Adeno-Associated Virus (AAV) Vector Production CDMO Revenue by Application (2020-2025) & (US$ Million)
Table 20. Global Adeno-Associated Virus (AAV) Vector Production CDMO Revenue by Application (2026-2031) & (US$ Million)
Table 21. Adeno-Associated Virus (AAV) Vector Production CDMO High-Growth Sectors Demand CAGR (2024-2031)
Table 22. Top Customers by Region
Table 23. Top Customers by Application
Table 24. North America Adeno-Associated Virus (AAV) Vector Production CDMO Growth Accelerators and Market Barriers
Table 25. North America Adeno-Associated Virus (AAV) Vector Production CDMO Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 26. Europe Adeno-Associated Virus (AAV) Vector Production CDMO Growth Accelerators and Market Barriers
Table 27. Europe Adeno-Associated Virus (AAV) Vector Production CDMO Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 28. Asia-Pacific Adeno-Associated Virus (AAV) Vector Production CDMO Growth Accelerators and Market Barriers
Table 29. Asia-Pacific Adeno-Associated Virus (AAV) Vector Production CDMO Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 30. Central and South America Adeno-Associated Virus (AAV) Vector Production CDMO Investment Opportunities and Key Challenges
Table 31. Central and South America Adeno-Associated Virus (AAV) Vector Production CDMO Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 32. Middle East and Africa Adeno-Associated Virus (AAV) Vector Production CDMO Investment Opportunities and Key Challenges
Table 33. Middle East and Africa Adeno-Associated Virus (AAV) Vector Production CDMO Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 34. Thermo Fisher Scientific Corporation Information
Table 35. Thermo Fisher Scientific Description and Major Businesses
Table 36. Thermo Fisher Scientific Product Features and Attributes
Table 37. Thermo Fisher Scientific Revenue (US$ Million) and Gross Margin (2020-2025)
Table 38. Thermo Fisher Scientific Revenue Proportion by Product in 2024
Table 39. Thermo Fisher Scientific Revenue Proportion by Application in 2024
Table 40. Thermo Fisher Scientific Revenue Proportion by Geographic Area in 2024
Table 41. Thermo Fisher Scientific Adeno-Associated Virus (AAV) Vector Production CDMO SWOT Analysis
Table 42. Thermo Fisher Scientific Recent Developments
Table 43. Lonza Corporation Information
Table 44. Lonza Description and Major Businesses
Table 45. Lonza Product Features and Attributes
Table 46. Lonza Revenue (US$ Million) and Gross Margin (2020-2025)
Table 47. Lonza Revenue Proportion by Product in 2024
Table 48. Lonza Revenue Proportion by Application in 2024
Table 49. Lonza Revenue Proportion by Geographic Area in 2024
Table 50. Lonza Adeno-Associated Virus (AAV) Vector Production CDMO SWOT Analysis
Table 51. Lonza Recent Developments
Table 52. Catalent Corporation Information
Table 53. Catalent Description and Major Businesses
Table 54. Catalent Product Features and Attributes
Table 55. Catalent Revenue (US$ Million) and Gross Margin (2020-2025)
Table 56. Catalent Revenue Proportion by Product in 2024
Table 57. Catalent Revenue Proportion by Application in 2024
Table 58. Catalent Revenue Proportion by Geographic Area in 2024
Table 59. Catalent Adeno-Associated Virus (AAV) Vector Production CDMO SWOT Analysis
Table 60. Catalent Recent Developments
Table 61. Charles River Corporation Information
Table 62. Charles River Description and Major Businesses
Table 63. Charles River Product Features and Attributes
Table 64. Charles River Revenue (US$ Million) and Gross Margin (2020-2025)
Table 65. Charles River Revenue Proportion by Product in 2024
Table 66. Charles River Revenue Proportion by Application in 2024
Table 67. Charles River Revenue Proportion by Geographic Area in 2024
Table 68. Charles River Adeno-Associated Virus (AAV) Vector Production CDMO SWOT Analysis
Table 69. Charles River Recent Developments
Table 70. Merck Corporation Information
Table 71. Merck Description and Major Businesses
Table 72. Merck Product Features and Attributes
Table 73. Merck Revenue (US$ Million) and Gross Margin (2020-2025)
Table 74. Merck Revenue Proportion by Product in 2024
Table 75. Merck Revenue Proportion by Application in 2024
Table 76. Merck Revenue Proportion by Geographic Area in 2024
Table 77. Merck Adeno-Associated Virus (AAV) Vector Production CDMO SWOT Analysis
Table 78. Merck Recent Developments
Table 79. SK pharmteco Corporation Information
Table 80. SK pharmteco Description and Major Businesses
Table 81. SK pharmteco Product Features and Attributes
Table 82. SK pharmteco Revenue (US$ Million) and Gross Margin (2020-2025)
Table 83. SK pharmteco Recent Developments
Table 84. Oxford Biomedica Corporation Information
Table 85. Oxford Biomedica Description and Major Businesses
Table 86. Oxford Biomedica Product Features and Attributes
Table 87. Oxford Biomedica Revenue (US$ Million) and Gross Margin (2020-2025)
Table 88. Oxford Biomedica Recent Developments
Table 89. AGC Biologics（MolMed） Corporation Information
Table 90. AGC Biologics（MolMed） Description and Major Businesses
Table 91. AGC Biologics（MolMed） Product Features and Attributes
Table 92. AGC Biologics（MolMed） Revenue (US$ Million) and Gross Margin (2020-2025)
Table 93. AGC Biologics（MolMed） Recent Developments
Table 94. Gene Universal Corporation Information
Table 95. Gene Universal Description and Major Businesses
Table 96. Gene Universal Product Features and Attributes
Table 97. Gene Universal Revenue (US$ Million) and Gross Margin (2020-2025)
Table 98. Gene Universal Recent Developments
Table 99. Polyplus (Sartorius) Corporation Information
Table 100. Polyplus (Sartorius) Description and Major Businesses
Table 101. Polyplus (Sartorius) Product Features and Attributes
Table 102. Polyplus (Sartorius) Revenue (US$ Million) and Gross Margin (2020-2025)
Table 103. Polyplus (Sartorius) Recent Developments
Table 104. CCRM Corporation Information
Table 105. CCRM Description and Major Businesses
Table 106. CCRM Product Features and Attributes
Table 107. CCRM Revenue (US$ Million) and Gross Margin (2020-2025)
Table 108. CCRM Recent Developments
Table 109. FUJIFILM Diosynth Biotechnologies Corporation Information
Table 110. FUJIFILM Diosynth Biotechnologies Description and Major Businesses
Table 111. FUJIFILM Diosynth Biotechnologies Product Features and Attributes
Table 112. FUJIFILM Diosynth Biotechnologies Revenue (US$ Million) and Gross Margin (2020-2025)
Table 113. FUJIFILM Diosynth Biotechnologies Recent Developments
Table 114. Biovian Corporation Information
Table 115. Biovian Description and Major Businesses
Table 116. Biovian Product Features and Attributes
Table 117. Biovian Revenue (US$ Million) and Gross Margin (2020-2025)
Table 118. Biovian Recent Developments
Table 119. Miltenyi Bioindustry Corporation Information
Table 120. Miltenyi Bioindustry Description and Major Businesses
Table 121. Miltenyi Bioindustry Product Features and Attributes
Table 122. Miltenyi Bioindustry Revenue (US$ Million) and Gross Margin (2020-2025)
Table 123. Miltenyi Bioindustry Recent Developments
Table 124. Aldevron Corporation Information
Table 125. Aldevron Description and Major Businesses
Table 126. Aldevron Product Features and Attributes
Table 127. Aldevron Revenue (US$ Million) and Gross Margin (2020-2025)
Table 128. Aldevron Recent Developments
Table 129. Takara Bio Corporation Information
Table 130. Takara Bio Description and Major Businesses
Table 131. Takara Bio Product Features and Attributes
Table 132. Takara Bio Revenue (US$ Million) and Gross Margin (2020-2025)
Table 133. Takara Bio Recent Developments
Table 134. Yposkesi Corporation Information
Table 135. Yposkesi Description and Major Businesses
Table 136. Yposkesi Product Features and Attributes
Table 137. Yposkesi Revenue (US$ Million) and Gross Margin (2020-2025)
Table 138. Yposkesi Recent Developments
Table 139. Genezen Corporation Information
Table 140. Genezen Description and Major Businesses
Table 141. Genezen Product Features and Attributes
Table 142. Genezen Revenue (US$ Million) and Gross Margin (2020-2025)
Table 143. Genezen Recent Developments
Table 144. Exthera Corporation Information
Table 145. Exthera Description and Major Businesses
Table 146. Exthera Product Features and Attributes
Table 147. Exthera Revenue (US$ Million) and Gross Margin (2020-2025)
Table 148. Exthera Recent Developments
Table 149. GenScript ProBio Corporation Information
Table 150. GenScript ProBio Description and Major Businesses
Table 151. GenScript ProBio Product Features and Attributes
Table 152. GenScript ProBio Revenue (US$ Million) and Gross Margin (2020-2025)
Table 153. GenScript ProBio Recent Developments
Table 154. EurekaBio Corporation Information
Table 155. EurekaBio Description and Major Businesses
Table 156. EurekaBio Product Features and Attributes
Table 157. EurekaBio Revenue (US$ Million) and Gross Margin (2020-2025)
Table 158. EurekaBio Recent Developments
Table 159. Obio Technology Corporation Information
Table 160. Obio Technology Description and Major Businesses
Table 161. Obio Technology Product Features and Attributes
Table 162. Obio Technology Revenue (US$ Million) and Gross Margin (2020-2025)
Table 163. Obio Technology Recent Developments
Table 164. GeneSail Biotech Corporation Information
Table 165. GeneSail Biotech Description and Major Businesses
Table 166. GeneSail Biotech Product Features and Attributes
Table 167. GeneSail Biotech Revenue (US$ Million) and Gross Margin (2020-2025)
Table 168. GeneSail Biotech Recent Developments
Table 169. VectorBuilder Corporation Information
Table 170. VectorBuilder Description and Major Businesses
Table 171. VectorBuilder Product Features and Attributes
Table 172. VectorBuilder Revenue (US$ Million) and Gross Margin (2020-2025)
Table 173. VectorBuilder Recent Developments
Table 174. WuXi ATU Corporation Information
Table 175. WuXi ATU Description and Major Businesses
Table 176. WuXi ATU Product Features and Attributes
Table 177. WuXi ATU Revenue (US$ Million) and Gross Margin (2020-2025)
Table 178. WuXi ATU Recent Developments
Table 179. Ubrigene Corporation Information
Table 180. Ubrigene Description and Major Businesses
Table 181. Ubrigene Product Features and Attributes
Table 182. Ubrigene Revenue (US$ Million) and Gross Margin (2020-2025)
Table 183. Ubrigene Recent Developments
Table 184. Porton Biologics Corporation Information
Table 185. Porton Biologics Description and Major Businesses
Table 186. Porton Biologics Product Features and Attributes
Table 187. Porton Biologics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 188. Porton Biologics Recent Developments
Table 189. Pharmaron Corporation Information
Table 190. Pharmaron Description and Major Businesses
Table 191. Pharmaron Product Features and Attributes
Table 192. Pharmaron Revenue (US$ Million) and Gross Margin (2020-2025)
Table 193. Pharmaron Recent Developments
Table 194. PackGene Biotechnology Corporation Information
Table 195. PackGene Biotechnology Description and Major Businesses
Table 196. PackGene Biotechnology Product Features and Attributes
Table 197. PackGene Biotechnology Revenue (US$ Million) and Gross Margin (2020-2025)
Table 198. PackGene Biotechnology Recent Developments
Table 199. Raw Materials Key Suppliers
Table 200. Distributors List
Table 201. Market Trends and Market Evolution
Table 202. Market Drivers and Opportunities
Table 203. Market Challenges, Risks, and Restraints
Table 204. Research Programs/Design for This Report
Table 205. Key Data Information from Secondary Sources
Table 206. Key Data Information from Primary Sources


List of Figures
Figure 1. Adeno-Associated Virus (AAV) Vector Production CDMO Product Picture
Figure 2. Global Adeno-Associated Virus (AAV) Vector Production CDMO Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Adherent Culture Product Picture
Figure 4. Suspension Culture Product Picture
Figure 5. Global Adeno-Associated Virus (AAV) Vector Production CDMO Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 6. Vaccine Development
Figure 7. Gene Therapy
Figure 8. Academic Scientific Research Institution
Figure 9. Others
Figure 10. Adeno-Associated Virus (AAV) Vector Production CDMO Report Years Considered
Figure 11. Global Adeno-Associated Virus (AAV) Vector Production CDMO Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 12. Global Adeno-Associated Virus (AAV) Vector Production CDMO Revenue (2020-2031) & (US$ Million)
Figure 13. Global Adeno-Associated Virus (AAV) Vector Production CDMO Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 14. Global Adeno-Associated Virus (AAV) Vector Production CDMO Revenue Market Share by Region (2020-2031)
Figure 15. Global Adeno-Associated Virus (AAV) Vector Production CDMO Revenue Market Share Ranking (2024)
Figure 16. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 17. Adherent Culture Revenue Market Share by Player in 2024
Figure 18. Suspension Culture Revenue Market Share by Player in 2024
Figure 19. Global Adeno-Associated Virus (AAV) Vector Production CDMO Revenue Market Share by Type (2020-2031)
Figure 20. Global Adeno-Associated Virus (AAV) Vector Production CDMO Revenue Market Share by Application (2020-2031)
Figure 21. North America Adeno-Associated Virus (AAV) Vector Production CDMO Revenue YoY (2020-2031) & (US$ Million)
Figure 22. North America Top 5 Players Adeno-Associated Virus (AAV) Vector Production CDMO Revenue (US$ Million) in 2024
Figure 23. North America Adeno-Associated Virus (AAV) Vector Production CDMO Revenue (US$ Million) by Type (2020 - 2031)
Figure 24. North America Adeno-Associated Virus (AAV) Vector Production CDMO Revenue (US$ Million) by Application (2020-2031)
Figure 25. US Adeno-Associated Virus (AAV) Vector Production CDMO Revenue (2020-2031) & (US$ Million)
Figure 26. Canada Adeno-Associated Virus (AAV) Vector Production CDMO Revenue (2020-2031) & (US$ Million)
Figure 27. Mexico Adeno-Associated Virus (AAV) Vector Production CDMO Revenue (2020-2031) & (US$ Million)
Figure 28. Europe Adeno-Associated Virus (AAV) Vector Production CDMO Revenue YoY (2020-2031) & (US$ Million)
Figure 29. Europe Top 5 Players Adeno-Associated Virus (AAV) Vector Production CDMO Revenue (US$ Million) in 2024
Figure 30. Europe Adeno-Associated Virus (AAV) Vector Production CDMO Revenue (US$ Million) by Type (2020-2031)
Figure 31. Europe Adeno-Associated Virus (AAV) Vector Production CDMO Revenue (US$ Million) by Application (2020-2031)
Figure 32. Germany Adeno-Associated Virus (AAV) Vector Production CDMO Revenue (2020-2031) & (US$ Million)
Figure 33. France Adeno-Associated Virus (AAV) Vector Production CDMO Revenue (2020-2031) & (US$ Million)
Figure 34. U.K. Adeno-Associated Virus (AAV) Vector Production CDMO Revenue (2020-2031) & (US$ Million)
Figure 35. Italy Adeno-Associated Virus (AAV) Vector Production CDMO Revenue (2020-2031) & (US$ Million)
Figure 36. Russia Adeno-Associated Virus (AAV) Vector Production CDMO Revenue (2020-2031) & (US$ Million)
Figure 37. Asia-Pacific Adeno-Associated Virus (AAV) Vector Production CDMO Revenue YoY (2020-2031) & (US$ Million)
Figure 38. Asia-Pacific Top 8 Players Adeno-Associated Virus (AAV) Vector Production CDMO Revenue (US$ Million) in 2024
Figure 39. Asia-Pacific Adeno-Associated Virus (AAV) Vector Production CDMO Revenue (US$ Million) by Type (2020-2031)
Figure 40. Asia-Pacific Adeno-Associated Virus (AAV) Vector Production CDMO Revenue (US$ Million) by Application (2020-2031)
Figure 41. Indonesia Adeno-Associated Virus (AAV) Vector Production CDMO Revenue (2020-2031) & (US$ Million)
Figure 42. Japan Adeno-Associated Virus (AAV) Vector Production CDMO Revenue (2020-2031) & (US$ Million)
Figure 43. South Korea Adeno-Associated Virus (AAV) Vector Production CDMO Revenue (2020-2031) & (US$ Million)
Figure 44. Australia Adeno-Associated Virus (AAV) Vector Production CDMO Revenue (2020-2031) & (US$ Million)
Figure 45. India Adeno-Associated Virus (AAV) Vector Production CDMO Revenue (2020-2031) & (US$ Million)
Figure 46. Indonesia Adeno-Associated Virus (AAV) Vector Production CDMO Revenue (2020-2031) & (US$ Million)
Figure 47. Vietnam Adeno-Associated Virus (AAV) Vector Production CDMO Revenue (2020-2031) & (US$ Million)
Figure 48. Malaysia Adeno-Associated Virus (AAV) Vector Production CDMO Revenue (2020-2031) & (US$ Million)
Figure 49. Philippines Adeno-Associated Virus (AAV) Vector Production CDMO Revenue (2020-2031) & (US$ Million)
Figure 50. Singapore Adeno-Associated Virus (AAV) Vector Production CDMO Revenue (2020-2031) & (US$ Million)
Figure 51. Central and South America Adeno-Associated Virus (AAV) Vector Production CDMO Revenue YoY (2020-2031) & (US$ Million)
Figure 52. Central and South America Top 5 Players Adeno-Associated Virus (AAV) Vector Production CDMO Revenue (US$ Million) in 2024
Figure 53. Central and South America Adeno-Associated Virus (AAV) Vector Production CDMO Revenue (US$ Million) by Type (2020-2031)
Figure 54. Central and South America Adeno-Associated Virus (AAV) Vector Production CDMO Revenue (US$ Million) by Application (2020-2031)
Figure 55. Brazil Adeno-Associated Virus (AAV) Vector Production CDMO Revenue (2020-2025) & (US$ Million)
Figure 56. Argentina Adeno-Associated Virus (AAV) Vector Production CDMO Revenue (2020-2025) & (US$ Million)
Figure 57. Middle East and Africa Adeno-Associated Virus (AAV) Vector Production CDMO Revenue YoY (2020-2031) & (US$ Million)
Figure 58. Middle East and Africa Top 5 Players Adeno-Associated Virus (AAV) Vector Production CDMO Revenue (US$ Million) in 2024
Figure 59. South America Adeno-Associated Virus (AAV) Vector Production CDMO Revenue (US$ Million) by Type (2020-2031)
Figure 60. Middle East and Africa Adeno-Associated Virus (AAV) Vector Production CDMO Revenue (US$ Million) by Application (2020-2031)
Figure 61. GCC Countries Adeno-Associated Virus (AAV) Vector Production CDMO Revenue (2020-2025) & (US$ Million)
Figure 62. Israel Adeno-Associated Virus (AAV) Vector Production CDMO Revenue (2020-2025) & (US$ Million)
Figure 63. Egypt Adeno-Associated Virus (AAV) Vector Production CDMO Revenue (2020-2025) & (US$ Million)
Figure 64. South Africa Adeno-Associated Virus (AAV) Vector Production CDMO Revenue (2020-2025) & (US$ Million)
Figure 65. Adeno-Associated Virus (AAV) Vector Production CDMO Industry Chain Mapping
Figure 66. Channels of Distribution (Direct Vs Distribution)
Figure 67. Bottom-up and Top-down Approaches for This Report
Figure 68. Data Triangulation
Figure 69. Key Executives Interviewed

Your Name

Your E-mail

Your message

Submit